Cargando…

A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)

In the era of rituximab, the International Prognostic Index (IPI) has been inefficient in initial risk stratification for patients with R‐CHOP‐treated diffuse large B‐cell lymphoma (DLBCL). To estimate the predictive values of PET/CT quantitative parameters and three prognostic models consisting of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi‐Yang, Song, Le, Zhao, Mei‐Xin, Hu, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718622/
https://www.ncbi.nlm.nih.gov/pubmed/31343111
http://dx.doi.org/10.1002/cam4.2284
_version_ 1783447758886141952
author Zhang, Yi‐Yang
Song, Le
Zhao, Mei‐Xin
Hu, Kai
author_facet Zhang, Yi‐Yang
Song, Le
Zhao, Mei‐Xin
Hu, Kai
author_sort Zhang, Yi‐Yang
collection PubMed
description In the era of rituximab, the International Prognostic Index (IPI) has been inefficient in initial risk stratification for patients with R‐CHOP‐treated diffuse large B‐cell lymphoma (DLBCL). To estimate the predictive values of PET/CT quantitative parameters and three prognostic models consisting of baseline and interim parameters for three‐year progression‐free survival (PFS), we conducted an analysis of 85 patients in China with DLBCL underwent baseline and interim PET/CT scans and treated at the Department of Hematology of Peking University Third Hospital from November 2012 to November 2017. The PET/CT parameters, viz. the baseline and interim values of standardized uptake value (SUV(max)), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG), and their rates of change, were analyzed by a receiver operating characteristics curve, Kaplan‐Meier analysis, and log‐rank test. Besides, the National Comprehensive Cancer Network International Prognostic Index (NCCN‐IPI) was also included in the multivariate Cox hazards model. Owing to the strong correlation between TMTV and TLG at baseline and interim (Pearson's correlation coefficient, r = 0.823, P‐value = 0.000, and 0.988, P‐value = 0.000, respectively), only TLG was included in the multivariate Cox hazards model, where TLG(0) > 1036.61 g and %ΔSUV(max) < 86.02% showed predictive value independently (HR = 10.42, 95% CI 2.35‐46.30, P = 0.002, and HR = 4.86, 95% CI 1.27‐18.54, P = 0.021, respectively). Replacing TLG in the equation, TMTV(0) and TMTV(1) both showed significantly predictive abilities like TLG (HR = 8.22, 95% CI 1.86‐32.24, P = 0.005, and HR = 2.96, 95% CI 1.16‐7.54, P = 0.023, respectively). After dichotomy, NCCN‐IPI also gave a significant performance (P = 0.035 and P = 0.010, respectively, in TLG and TMTV models). The baseline variables, that is, TMTV(0), TLG(0) and dichotomized NCCN‐IPI, and the interim variables TMTV(1) and %ΔSUV(max), presented independent prognostic value for PFS. In prognostic model 2 (TLG(0) + %ΔSUV(max)), the group with TLG(0) > 1036.61 g and %ΔSUV(max) < 86.02% recognized 19 (82.6%) of the relapse or progression events, which showed the best screening ability among three models consisting of baseline and interim PET/CT parameters.
format Online
Article
Text
id pubmed-6718622
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67186222019-09-06 A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max) Zhang, Yi‐Yang Song, Le Zhao, Mei‐Xin Hu, Kai Cancer Med Clinical Cancer Research In the era of rituximab, the International Prognostic Index (IPI) has been inefficient in initial risk stratification for patients with R‐CHOP‐treated diffuse large B‐cell lymphoma (DLBCL). To estimate the predictive values of PET/CT quantitative parameters and three prognostic models consisting of baseline and interim parameters for three‐year progression‐free survival (PFS), we conducted an analysis of 85 patients in China with DLBCL underwent baseline and interim PET/CT scans and treated at the Department of Hematology of Peking University Third Hospital from November 2012 to November 2017. The PET/CT parameters, viz. the baseline and interim values of standardized uptake value (SUV(max)), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG), and their rates of change, were analyzed by a receiver operating characteristics curve, Kaplan‐Meier analysis, and log‐rank test. Besides, the National Comprehensive Cancer Network International Prognostic Index (NCCN‐IPI) was also included in the multivariate Cox hazards model. Owing to the strong correlation between TMTV and TLG at baseline and interim (Pearson's correlation coefficient, r = 0.823, P‐value = 0.000, and 0.988, P‐value = 0.000, respectively), only TLG was included in the multivariate Cox hazards model, where TLG(0) > 1036.61 g and %ΔSUV(max) < 86.02% showed predictive value independently (HR = 10.42, 95% CI 2.35‐46.30, P = 0.002, and HR = 4.86, 95% CI 1.27‐18.54, P = 0.021, respectively). Replacing TLG in the equation, TMTV(0) and TMTV(1) both showed significantly predictive abilities like TLG (HR = 8.22, 95% CI 1.86‐32.24, P = 0.005, and HR = 2.96, 95% CI 1.16‐7.54, P = 0.023, respectively). After dichotomy, NCCN‐IPI also gave a significant performance (P = 0.035 and P = 0.010, respectively, in TLG and TMTV models). The baseline variables, that is, TMTV(0), TLG(0) and dichotomized NCCN‐IPI, and the interim variables TMTV(1) and %ΔSUV(max), presented independent prognostic value for PFS. In prognostic model 2 (TLG(0) + %ΔSUV(max)), the group with TLG(0) > 1036.61 g and %ΔSUV(max) < 86.02% recognized 19 (82.6%) of the relapse or progression events, which showed the best screening ability among three models consisting of baseline and interim PET/CT parameters. John Wiley and Sons Inc. 2019-07-25 /pmc/articles/PMC6718622/ /pubmed/31343111 http://dx.doi.org/10.1002/cam4.2284 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Zhang, Yi‐Yang
Song, Le
Zhao, Mei‐Xin
Hu, Kai
A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
title A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
title_full A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
title_fullStr A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
title_full_unstemmed A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
title_short A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
title_sort better prediction of progression‐free survival in diffuse large b‐cell lymphoma by a prognostic model consisting of baseline tlg and %δsuv(max)
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718622/
https://www.ncbi.nlm.nih.gov/pubmed/31343111
http://dx.doi.org/10.1002/cam4.2284
work_keys_str_mv AT zhangyiyang abetterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax
AT songle abetterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax
AT zhaomeixin abetterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax
AT hukai abetterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax
AT zhangyiyang betterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax
AT songle betterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax
AT zhaomeixin betterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax
AT hukai betterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax